What is Cutaneous Mastocytosis?
Cutaneous Mastocytosis (CM) is a rare skin disorder. It is characterised by the accumulation of mast cells in the skin.1 Mast cells (a type of white blood cell) play a crucial role in the body’s immune response and allergic reactions. These cells proliferate excessively (rapidly multiply) in CM, leading to various skin issues. The condition can range from mild to severe and significantly impact the patient’s quality of life. CM is part of a broader group of disorders known as mastocytosis, which can affect multiple organs (systemic mastocytosis) or be confined to the skin (cutaneous mastocytosis).
Cutaneous Mastocytosis is a rare condition. Worldwide, the prevalence of mastocytosis is estimated to be 1 in every 10,000 people.2 It affects both males and females equally3. CM is more commonly diagnosed in children, with many cases resolving before adulthood. However, adults can also be affected, often with a later onset and typically more persistent symptoms.
What are the subtypes?
CM is classified into several subtypes:4
- Maculopapular Cutaneous Mastocytosis (MPCM): Also known as urticaria pigmentosa, characterised by brownish or reddish spots or plaques
- Diffuse Cutaneous Mastocytosis (DCM): Involves widespread thickening and blistering of the skin
- Solitary Mastocytoma: A single lesion, typically seen in children but can occur in adults
What are the causes of Cutaneous Mastocytosis?
The actual cause of CM manifestation is not clearly understood. However, genetic mutations could play a significant role. The KIT gene encodes the c-kit protein and is commonly mutated in individuals with CM. This protein is crucial for mast cell growth and survival. Mutations in the KIT gene lead to uncontrolled growth and accumulation of mast cells in the skin.
What are the symptoms associated with Cutaneous mastocytosis?
Symptoms can range in severity and are often triggered by external factors.
Common symptoms
- Skin Lesions:
- Maculopapular Cutaneous Mastocytosis (MPCM): Brownish or reddish spots or raised lesions, primarily on the trunk
- Diffuse Cutaneous Mastocytosis (DCM): Widespread skin thickening and, in severe cases, blistering
- Darier’s Sign:5
- Lesions become raised, red, and itchy when rubbed due to histamine release
- Pruritus (Itching):
- Severe itching can occur, often worsened by heat, stress, or medications
- Flushing:
- Sudden redness and warmth, usually on the face and upper body, triggered by temperature changes, stress, alcohol, or spicy foods
- Blistering:
- Painful blisters are more common in severe cases
- Dermatographism:
- Skin becomes raised and inflamed upon scratching or pressure
- Pigmentation Changes:
- Affected skin may show changes in colour, either darker or lighter
- Systemic Symptoms:
- Occasionally, mild systemic symptoms like headaches, gastrointestinal issues, or palpitations may occur
Triggers
Symptoms can be exacerbated by:
- Temperature Changes: Both heat and cold
- Physical Stimuli: Pressure, friction, or scratching
- Emotional Stress: Stress and anxiety
- Foods and Beverages: Certain foods, alcohol, and additives
- Medications: Pain-relieving drugs like opioids and NSAIDs
How can Cutaneous Mastocytosis be diagnosed?
Diagnosing cutaneous mastocytosis (CM) involves several steps, including a physical examination, skin biopsy, and various laboratory tests.
- Medical History and Physical Examination:
- Take a detailed medical history, focusing on symptoms such as skin lesions, itching, flushing, and any known triggers
- A thorough physical examination of the skin will be conducted to look for characteristic lesions.
- Skin Biopsy:
- A small sample of the affected skin is taken and examined under a microscope. This helps confirm an abnormal number of mast cells in the skin
- Laboratory Tests:
- Blood Tests: These may include measuring levels of tryptase, a protein mast cells release. Elevated tryptase levels can indicate mast cell disorders
- Urine Tests: Testing for histamine metabolites can help assess mast cell activity
- Specialized Tests:
- Dermatographism Test: This involves gently scratching the skin to see if it becomes raised and inflamed (Darier's sign)
- Genetic Testing: In some cases, genetic tests may be performed to identify mutations associated with mastocytosis
- Additional Imaging:
- Sometimes, imaging tests such as ultrasound or MRI may be used to check for involvement of other organs, although this is more common in systemic mastocytosis
How is Cutaneous Mastocytosis treated?
The main aim of treating cutaneous mastocytosis involves managing and relieving the symptoms and preventing potential triggers.
- Avoiding Triggers:
- Identifying and avoiding factors that trigger symptoms, such as certain foods, medications, temperature changes, and stress, is crucial
- Medications:
- Antihistamines: These are the first line of treatment and help control itching and reduce flushing. They work by blocking the effects of histamine, a chemical mast cells release
- Corticosteroids: This drug, when applied topically, could reduce inflammation and itching of the affected skin
- Mast Cell Stabilizers: Medications such as cromolyn sodium can help stabilise mast cells and prevent them from releasing histamine
- Leukotriene Inhibitors: These drugs can help reduce symptoms by blocking leukotrienes, other chemicals released by mast cells
- Epinephrine: In cases of severe allergic reactions or anaphylaxis, an epinephrine auto-injector (EpiPen) may be prescribed for emergency use
- Phototherapy:
- Light therapy (phototherapy) using ultraviolet light can help reduce the number of mast cells in the skin and alleviate symptoms. This treatment is typically administered in a clinical setting
- Immunotherapy:
- In some cases, immunotherapy may be considered to modulate the immune system’s response and reduce symptoms
- Lifestyle Adjustments:
- Wear loose, comfortable clothing to avoid skin irritation
- Using mild, fragrance-free skin care products
- Maintaining a cool environment to prevent heat-induced symptoms
- Supportive Care:
- Support groups could help connect with other patients and build a sense of community. Emotional and psychological impact on the patient’s life could be managed through psychological support and counselling
Prognosis and quality of life in Cutaneous Mastocytosis
In adults, cutaneous mastocytosis (CM) typically presents as a chronic condition with a variable prognosis. The most common form, maculopapular cutaneous mastocytosis (MPCM), usually persists without spontaneous resolution, unlike in children, where symptoms may improve or resolve over time. Adult CM rarely progresses to systemic mastocytosis (SM), but monitoring for systemic involvement is crucial. Factors that influence prognosis include the severity of the lesions, effectiveness, and response to treatment, as well as the presence of other complications or systemic symptoms. While many adults manage symptoms effectively with appropriate treatments, some may experience persistent or worsening symptoms requiring ongoing medical intervention.
CM significantly impacts the quality of life due to chronic symptoms such as itching, flushing, and visible skin lesions. These symptoms can interfere with daily activities, sleep, and overall well-being. The emotional and psychological toll includes stress, anxiety, and depression, exacerbated by the unpredictability of symptom flare-ups and the need to avoid numerous triggers. Social interactions and lifestyle choices are often restricted, affecting dining out, travel, and participation in physical activities.
Frequent medical visits and the need for continuous medication can be both time-consuming and financially burdensome. Side effects from medications further complicate the management of CM. Emotional support from family, friends, and support groups plays a vital role in coping with the condition. These support systems provide practical assistance and a sense of community and understanding.
In summary, while CM in adults is a chronic condition with no cure, effective management and a comprehensive care approach can significantly improve the quality of life. Regular medical follow-up, tailored treatment plans, and strong support systems are essential in managing the physical and emotional challenges of cutaneous mastocytosis.
Summary
Cutaneous mastocytosis in adults is a rare but manageable condition. Many patients can lead a relatively normal life with proper diagnosis and treatment. However, ongoing research and advancements in medical therapies are essential to improve the understanding and management of this complex disorder. If you suspect you have symptoms of cutaneous mastocytosis, it is important to seek medical advice for proper evaluation and treatment.
References
- Czarny J, Lange M, Ługowska-Umer H, Nowicki RJ. Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Postepy Dermatol Alergol [Internet]. 2018 Dec [cited 2024 Jun 22];35(6):541–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320483/
- Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunology and Allergy Clinics of North America [Internet]. 2014 May [cited 2024 Jun 22];34(2):283–95. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0889856114000046
- Kaszuba A, Sławińska M, Żółkiewicz J, Sobjanek M, Nowicki RJ, Lange M. Mastocytosis and skin cancer: the current state of knowledge. Int J Mol Sci [Internet]. 2023 Jun 7 [cited 2024 Jun 22];24(12):9840. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298540/
- Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the european competence network on mastocytosis; the american academy of allergy, asthma & immunology; and the european academy of allergology and clinical immunology. Journal of Allergy and Clinical Immunology [Internet]. 2016 Jan [cited 2024 Jun 22];137(1):35–45. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0091674915012580
- Macri A, Cook C. Urticaria pigmentosa. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Jun 22]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482503/

